Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: Insights into protein alterations consistent with the pathology and progression of this dementing disorder

Proteomics - Clinical Applications

Volumn 5, Issue 1-2, 2011, Pages 50-56

  Butterfield, D Allan ^a   Owen, Joshua B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimers disease (AD); Lectin chromatography; Mild cognitive impairment (MCI); MS; Synaptic alterations

Indexed keywords

CONCANAVALIN A; GLYCOPROTEIN; LECTIN; PEANUT AGGLUTININ; WHEAT GERM AGGLUTININ;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; BINDING AFFINITY; DISEASE COURSE; DISEASE MARKER; GLUCOSE UTILIZATION; HUMAN; LECTIN BINDING SITE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC INHIBITION;

ALZHEIMER DISEASE; BRAIN; CHROMATOGRAPHY, AFFINITY; COGNITION DISORDERS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LECTINS; MASS SPECTROMETRY;

TRITICUM AESTIVUM;

EID: 79251552289     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000070     Document Type: Review

References (66)

1. Maslow, K., Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6, 158-194.
2. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G. et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245-4249.
3. Hardy, J. A., Higgins, G. A., Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256, 184-185.
4. Selkoe, D. J., The molecular pathology of Alzheimer's disease. Neuron 1991, 6, 487-498.
5. Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K. et al., Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17, 1005-1013.
6. Citron, M., Westaway, D., Xia, W., Carlson, G. et al., Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3, 67-72.
7. De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H. et al., Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391, 387-390.
8. Duff, K., Eckman, C., Zehr, C., Yu, X. et al., Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383, 710-713.
9. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M. et al., Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269, 973-977.
10. Scheuner, D., Eckman, C., Jensen, M., Song, X. et al., Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2, 864-870.
11. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A. et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375, 754-760.
12. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S. et al., Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398, 513-517.
13. Selkoe, D. J., Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 2004, 6, 1054-1061.
14. Suzuki, T., Araki, Y., Yamamoto, T., Nakaya, T., Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J. Biochem. 2006, 139, 949-955.
15. Hwang, H., Zhang, J., Chung, K. A., Leverenz, J. B. et al., Glycoproteomics in neurodegenerative diseases. Mass Spectrom. Rev. 2010, 29, 79-125.
16. Goldstein, I. J., Hollerman, C. E., Smith, E. E., Protein-carbohydrate interaction. II. Inhibition studies on the interaction of concanavalin A with polysaccharides. Biochemistry 1965, 4, 876-883.
17. Kamra, A., Gupta, M. N., Crosslinked concanavalin A-O-(diethylaminoethyl)-cellulose - an affinity medium for concanavalin A-interacting glycoproteins. Anal. Biochem. 1987, 164, 405-410.
18. Yahara, I., Edelman, G. M., Restriction of the mobility of lymphocyte immunoglobulin receptors by concanavalin A. Proc. Natl. Acad. Sci. USA 1972, 69, 608-612.
19. Edelman, G. M., Wang, J. L., Binding and functional properties of concanavalin A and its derivatives. III. Interactions with indoleacetic acid and other hydrophobic ligands. J. Biol. Chem. 1978, 253, 3016-3022.
20. Owen, J. B., Di Domenico, F., Sultana, R., Perluigi, M. et al., Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J. Proteome Res. 2009, 8, 471-482.
21. Nagata, Y., Burger, M. M., Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. J. Biol. Chem. 1974, 249, 3116-3122.
22. Novogrodsky, A., Lotan, R., Ravid, A., Sharon, N., Peanut agglutinin, a new mitogen that binds to galactosyl sites exposed after neuraminidase treatment. J. Immunol. 1975, 115, 1243-1248.
23. Yamashita, K., Totani, K., Ohkura, T., Takasaki, S. et al., Carbohydrate binding properties of complex-type oligosaccharides on immobilized Datura stramonium lectin. J. Biol. Chem. 1987, 262, 1602-1607.
24. Saulsbury, F. T., Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schonlein purpura. J. Rheumatol. 1997, 24, 2246-2249.
25. Yang, Z., Hancock, W. S., Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J. Chromatogr. A 2004, 1053, 79-88.
26. Yates, J. R., Ruse, C. I., Nakorchevsky, A., Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 2009, 11, 49-79.
27. Zhou, Y., Aebersold, R., Zhang, H., Isolation of N-linked glycopeptides from plasma. Anal. Chem. 2007, 79, 5826-5837.
28. Hart, G. W., Housley, M. P., Slawson, C., Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007, 446, 1017-1022.
29. Hanisch, F. G., Jovanovic, M., Peter-Katalinic, J., Glycoprotein identification and localization of O-glycosylation sites by mass spectrometric analysis of deglycosylated/alkylaminylated peptide fragments. Anal. Biochem. 2001, 290, 47-59.
30. Rademaker, G. J., Pergantis, S. A., Blok-Tip, L., Langridge, J. I. et al., Mass spectrometric determination of the sites of O-glycan attachment with low picomolar sensitivity. Anal. Biochem. 1998, 257, 149-160.
31. Loredo-Abdala, A., Mata-Quezada, L. C., Carbajal-Rodriguez, L., Villasenor-Zepeda, J., Hepatosplenomegaly of unknown etiology: clinical examination in making a diagnosis in 57 cases. Bol. Med. Hosp. Infant. Mex. 1989, 46, 41-46.
32. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
33. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. et al., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
34. Han, D. K., Eng, J., Zhou, H., Aebersold, R., Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 2001, 19, 946-951.
35. Haynes, P. A., Aebersold, R., Simultaneous detection and identification of O-GlcNAc-modified glycoproteins using liquid chromatography-tandem mass spectrometry. Anal. Chem. 2000, 72, 5402-5410.
36. McGeer, P. L., Klegeris, A., Walker, D. G., Yasuhara, O., et al., Pathological proteins in senile plaques. Tohoku J. Exp. Med. 1994, 174, 269-277.
37. Salminen, A., Kaarniranta, K., Siglec receptors and hiding plaques in Alzheimer's disease. J. Mol. Med. 2009, 87, 697-701.
38. Li, X., Lu, F., Wang, J. Z., Gong, C. X., Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur. J. Neurosci. 2006, 23, 2078-2086.
39. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., et al., O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2004, 101, 10804-10809.
40. Liu, F., Shi, J., Tanimukai, H., Gu, J. et al., Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 2009, 132, 1820-1832.
41. Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I., et al., Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 2002, 115, 829-837.
42. Heiss, W. D., Szelies, B., Kessler, J., Herholz, K., Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann. NY Acad. Sci. 1991, 640, 65-71.
43. McGeer, E. G., McGeer, P. L., Akiyama, H., Harrop, R., Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease. Can. J. Neurol. Sci. 1989, 16, 511-515.
44. McGeer, E. G., Peppard, R. P., McGeer, P. L., Tuokko, H. et al., 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can. J. Neurol. Sci. 1990, 17, 1-11.
45. Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L., et al., A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 1995, 36, 1238-1248.
46. Smith, G. S., de Leon, M. J., George, A. E., Kluger, A. et al., Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch. Neurol. 1992, 49, 1142-1150.
47. de Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y. et al., Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 2001, 98, 10966-10971.
48. Drzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N. et al., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 2005, 46, 1625-1632.
49. Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M. et al., Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1104-1113.
50. Mielke, R., Herholz, K., Grond, M., Kessler, J., et al., Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994, 5, 36-41.
51. Mosconi, L., Perani, D., Sorbi, S., Herholz, K. et al., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63, 2332-2340.
52. Mosconi, L., Tsui, W. H., Rusinek, H., De Santi, S. et al., Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 1467-1479.
53. Pietrini, P., Azari, N. P., Grady, C. L., Salerno, J. A. et al., Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. Dementia 1993, 4, 94-101.
54. LaFerla, F. M., Oddo, S., Alzheimer's disease: abeta, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11, 170-176.
55. Selkoe, D. J., Alzheimer's disease is a synaptic failure. Science 2002, 298, 789-791.
56. Tallent, M. K., Varghis, N., Skorobogatko, Y., Hernandez-Cuebas, L. et al., In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J. Biol. Chem. 2009, 284, 174-181.
57. Skorobogatko, Y. V., Deuso, J., Adolf-Bergfoyle, J., Nowak, M. G. et al., Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry. Amino Acids 2010 (in press).
58. Fenster, S. D., Chung, W. J., Zhai, R., Cases-Langhoff, C. et al., Piccolo, a presynaptic zinc finger protein structurally related to bassoon. Neuron 2000, 25, 203-214.
59. Inoue, E., Deguchi-Tawarada, M., Takao-Rikitsu, E., Inoue, M. et al., ELKS, a protein structurally related to the active zone protein CAST, is involved in Ca2+-dependent exocytosis from PC12 cells. Genes Cells 2006, 11, 659-672.
60. Leal-Ortiz, S., Waites, C. L., Terry-Lorenzo, R., Zamorano, P. et al., Piccolo modulation of Synapsin1a dynamics regulates synaptic vesicle exocytosis. J. Cell. Biol. 2008, 181, 831-846.
61. Takao-Rikitsu, E., Mochida, S., Inoue, E., Deguchi-Tawarada, M. et al., Physical and functional interaction of the active zone proteins, CAST, RIM1, and Bassoon, in neurotransmitter release. J. Cell Biol. 2004, 164, 301-311.
62. Hlavanda, E., Klement, E., Kokai, E., Kovacs, J. et al., Phosphorylation blocks the activity of tubulin polymerization-promoting protein (TPPP): identification of sites targeted by different kinases. J. Biol. Chem. 2007, 282, 29531-29539.
63. Sweatt, J. D., Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 2004, 14, 311-317.
64. Yao, T., Song, L., Xu, W., DeMartino, G. N. et al., Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat. Cell Biol. 2006, 8, 994-1002.
65. Butterfield, D. A., Sultana, R., Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 2007, 12, 61-72.
66. Butterfield, D. A., Lange, M. L., Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 2009, 111, 915-933.